The pharmaceutical industry stands at a critical juncture, contending with a deep and persistent deficit of public trust that can significantly impede medical progress and patient care. While this challenge is formidable, it is not an insurmountable barrier to a more collaborative future. Recent
With a deep background in biopharma and a keen eye on the intersection of technology and research, Ivan Kairatov has become a leading voice on innovative public health strategies. Today, he joins us to discuss a unique cause-marketing campaign that transforms the retail experience into a powerful
In the high-stakes world of pharmaceutical development, not all clinical successes translate to commercial triumphs, a reality starkly illustrated when Amgen announced it was terminating its partnership with Kyowa Kirin for the eczema drug rocatinlimab, handing back the rights to a once-promising
Today we are speaking with Ivan Kairatov, a biopharma expert with deep insight into the intersection of technology and research in mental healthcare. We will be exploring the UK's ambitious new Mental Health Goals programme, a transformative initiative poised to reshape how we understand and treat
For the millions of people living with Parkinson's disease, the diagnosis often arrives like a conclusion to a story whose beginning was missed, confirming a devastating neurological decline that has been silently underway for years. The core challenge in managing this progressive disorder, which
A strategic maneuver from the titan of mRNA vaccine technology has shifted a potentially life-changing therapy for a rare disease into the hands of a specialized pharmaceutical firm, signaling a significant recalibration of priorities for both companies. In a deal that highlights the complex
